RankAlpha logo
Back to Rankings

CLPT

ClearPoint NeuroD
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
View Chart
Current thesis
The bull read after earnings is that CLPT delivered record revenue, 16% organic total growth, 25% organic device growth, higher gross margin, and maintained a full-year revenue outlook while pointing to IRRAS revenue and cost synergies in 2H26 [#8-K-2026-05-13].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +6.5.
What can break
Growth depends in part on partner clinical, regulatory, and funding progress across the biopharma pipeline, which management does not fully control [#10-Q-2026-05-13].
Momentum
68
Value
36
Sentiment
39
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $11.00 · Bull $17.00 · Bear $7.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $29.00
Why
Momentum68 · Δ7d +6.5
Value36 · Δ7d -0.0
Sentiment39 · Δ7d -6.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
68
34% active weight
Current posture
7d trendSoftening
Δ7d
+6.5
Δ21d
-10.1
Value
36
32% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
39
33% active weight
Current posture
7d trendSoftening
Δ7d
-6.7
Δ21d
-61.4
Why this grade

Composite grade D. Momentum 68.4 / Value 36.4 / Sentiment 38.6

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$379.07M
Beta
1.02
Shares Out
29.75M
P/E (TTM) · Derived
-18.2
P/S (TTM)
12.30
P/FCF (TTM) · Derived
-25.81
Rev YoY
+9.1%
EPS YoY
-15.0%
Gross Margin
+61.3%
Op Margin
-66.2%
Net Debt
-$20.1M
Current Ratio
6.37
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology